At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)
In Brief
A Phase 2 clinical trial evaluating bendamustine hydrochloride, dexamethasone, and 5 other interventions for Adult Nasal Type Extranodal NK/T-cell Lymphoma and 28 related conditions. Completed, enrolled 43 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving bendamustine hydrochloride, etoposide, dexamethasone, and filgrastim together for peripheral stem cell mobilization works in treating patients with refractory or recurrent lymphoma or multiple myeloma. Giving chemotherapy, such as bendamustine hydrochloride, etoposide, and dexamethasone, before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim, and certain chemotherapy drugs helps stem cells move from the bone marrow to the blood so they can be collected and stored
Study Details
Timeline
Interventions
Given IV
Given PO
Given SC
Given IV
Correlative studies
Correlative studies
Given IV